LIF might produce biogenerics

     Last month an important agreement of “Mutual collaboration and assistance” was signed between LIF SE and Zelltek SA.
     Zelltek SA produces active biopharmaceutical ingredients in a production site located at the Parque Tecnológico Litoral Centro (Santa Fe). 
    Due to this agreement, LIF will be able to produce biogenerics as Erythropoietin, Interferon and Filgrastim. Thus, LIF would add a new products line in its portfolio which so far only includes medicines for primary healthcare.
     At the beginning, these biogenerics will be delivered by the Health Ministry of Santa Fe. But then, they will be available for other public health systems.
     Through this project, LIF‘s idea is to sell this products at almost cost price.
     Anemia, Chronic Myelogenous Leukemia, Hairy Cell Leukemia, Chronic Hepatitis C, Hepatitis B, Multiple Sclerosis, Leukapheresis and Neutropenia are some diseases which require these biogenerics as part of their treatment.